Amphastar initiated with an Overweight at JPMorgan

JPMorgan initiated coverage of Amphastar Pharmaceuticals with an Overweight rating and $60 price target. The analyst sees Amphastar as a good way to get exposure to the specialty pharma space. The company offers a diverse and attractive collection of assets, says the analyst, who see Baqsimi expanding its presence in the hypoglycemia market and adding an important growth driver to the story.